740.73

1.06% -8.14

Regeneron Pharmaceuticals Inc (REGN)

Overview News Price History Option Chain Financials Why REGN Down? Discussions Forecast

Regeneron Pharmaceuticals Inc stock is traded at $740.73, with a volume of 167.44K. It is down -1.06% in the last 24 hours and down -0.65% over the past month. Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Previous Close:

$748.87

Open:

$747.74

24h Volume:

167.44K

Relative Volume:

0.23

Market Cap:

$78.33B

Revenue:

$14.34B

Net Income/Loss:

$4.50B

P/E Ratio:

17.82

EPS:

41.5626

Net Cash Flow:

$3.77B

1W Performance:

-2.90%

1M Performance:

-0.65%

6M Performance:

+32.85%

1Y Performance:

+33.70%

1-Day Range:

$738.52

$756.90

1-Week Range:

$738.52

$775.62

52-Week Range:

$476.49

$821.11

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name

Regeneron Pharmaceuticals Inc

Sector

Healthcare (1111)

Industry

Biotechnology (623)

Phone

(914) 847-7000

Address

777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY

Employee

15,410

Twitter

@regeneron

Next Earnings Date

2026-01-30

Latest SEC Filings

REGN's Discussions on Twitter

Compare REGN vs VRTX, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
REGN Regeneron Pharmaceuticals Inc	740.89	79.17B	14.34B	4.50B	3.77B	41.56
VRTX Vertex Pharmaceuticals Inc	437.92	110.97B	12.07B	3.95B	3.19B	15.33
ARGX Argen X Se Adr	791.70	49.73B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	326.71	42.98B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	306.46	34.37B	5.36B	287.73M	924.18M	2.5229

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-31-26	Resumed	Piper Sandler	Overweight
Mar-06-26	Initiated	Barclays	Overweight
Jan-07-26	Upgrade	BofA Securities	Underperform → Buy
Dec-03-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-24-25	Initiated	HSBC Securities	Buy
Nov-24-25	Resumed	Truist	Buy
Nov-13-25	Initiated	Scotiabank	Sector Perform
Aug-14-25	Initiated	Rothschild & Co Redburn	Buy
Jun-30-25	Downgrade	Argus	Buy → Hold
May-30-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
May-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight
May-14-25	Upgrade	Citigroup	Neutral → Buy
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight
Feb-05-25	Upgrade	Leerink Partners	Market Perform → Outperform
Jan-16-25	Downgrade	UBS	Buy → Neutral
Dec-10-24	Resumed	BofA Securities	Underperform
Nov-15-24	Initiated	Wolfe Research	Outperform
Nov-14-24	Initiated	Citigroup	Neutral
Sep-24-24	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-12-24	Initiated	Bernstein	Outperform
Jan-12-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Nov-09-23	Initiated	Deutsche Bank	Hold
Nov-03-23	Upgrade	Raymond James	Mkt Perform → Outperform
Aug-21-23	Upgrade	Canaccord Genuity	Hold → Buy
Aug-21-23	Reiterated	Oppenheimer	Perform
Jun-28-23	Downgrade	Canaccord Genuity	Buy → Hold
Mar-27-23	Upgrade	SVB Securities	Market Perform → Outperform
Mar-24-23	Upgrade	Jefferies	Hold → Buy
Mar-23-23	Upgrade	Raymond James	Underperform → Mkt Perform
Jan-30-23	Upgrade	Cowen	Market Perform → Outperform
Jan-20-23	Upgrade	JP Morgan	Neutral → Overweight
Oct-26-22	Downgrade	Raymond James	Mkt Perform → Underperform
Oct-17-22	Downgrade	Evercore ISI	Outperform → In-line
Sep-09-22	Upgrade	Jefferies	Underperform → Hold
Sep-09-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-25-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral
Jun-06-22	Initiated	Jefferies	Underperform
May-23-22	Initiated	SVB Leerink	Outperform
Jan-05-22	Downgrade	BofA Securities	Neutral → Underperform
Jan-03-22	Upgrade	Bernstein	Mkt Perform → Outperform
Dec-15-21	Downgrade	Bernstein	Outperform → Mkt Perform
Dec-09-21	Resumed	Wells Fargo	Overweight
Dec-07-21	Resumed	Cowen	Market Perform
Dec-06-21	Initiated	Goldman	Buy
Nov-19-21	Resumed	BMO Capital Markets	Outperform
Nov-05-21	Downgrade	The Benchmark Company	Buy → Hold
Jun-29-21	Initiated	H.C. Wainwright	Buy
Jan-25-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jan-13-21	Upgrade	The Benchmark Company	Hold → Buy
Jan-08-21	Upgrade	Citigroup	Neutral → Buy
Oct-05-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Aug-20-20	Downgrade	The Benchmark Company	Buy → Hold
Jul-09-20	Upgrade	SunTrust	Hold → Buy
May-26-20	Upgrade	Wells Fargo	Equal Weight → Overweight
Apr-28-20	Downgrade	Citigroup	Buy → Neutral
Apr-17-20	Upgrade	The Benchmark Company	Hold → Buy
Apr-08-20	Initiated	The Benchmark Company	Hold
Mar-31-20	Initiated	Wolfe Research	Peer Perform
Feb-27-20	Initiated	Barclays	Overweight
Feb-26-20	Upgrade	Canaccord Genuity	Hold → Buy
Feb-26-20	Downgrade	Robert W. Baird	Outperform → Neutral
Feb-25-20	Upgrade	Jefferies	Hold → Buy
Feb-11-20	Upgrade	Argus	Hold → Buy
Dec-24-19	Initiated	Raymond James	Mkt Perform
Dec-16-19	Downgrade	Evercore ISI	Outperform → In-line
Dec-13-19	Upgrade	Credit Suisse	Neutral → Outperform
Nov-12-19	Initiated	SunTrust	Hold
Nov-07-19	Upgrade	Citigroup	Neutral → Buy
Oct-17-19	Resumed	BofA/Merrill	Neutral
Sep-23-19	Upgrade	Guggenheim	Neutral → Buy

View All

Regeneron Pharmaceuticals Inc Stock (REGN) Latest News

09:35 AM

The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026 - FinancialContent

09:35 AM

09:07 AM

Regeneron Pharmaceuticals (REGN) Partners with Telix for Radioph - GuruFocus

09:07 AM

09:00 AM

Neomorph Announces Closing of $100 Million Series B Financing - GlobeNewswire Inc.

09:00 AM

08:45 AM

Regeneron enters radiopharma ring with up to $4.3B Telix alliance - BioSpace

08:45 AM

08:38 AM

Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs - Benzinga

08:38 AM

08:09 AM

Regeneron, Sanofi Get Expanded Europe OK for Dupixent in Younger Children With CSU - National Today

08:09 AM

07:37 AM

Regeneron (REGN) Partners with Telix Pharmaceuticals - GuruFocus

07:37 AM

07:29 AM

H.C. Wainwright reiterates Telix stock rating on Regeneron deal - Investing.com

07:29 AM

07:21 AM

Regeneron, Telix partner on radiopharmaceutical cancer therapies By Investing.com - Investing.com Canada

07:21 AM

07:09 AM

Regeneron (REGN) Partners with Telix Pharmaceuticals for Innovat - GuruFocus

07:09 AM

06:48 AM

Telix and Regeneron to co-develop radiopharmaceutical therapies - Yahoo Finance

06:48 AM

06:33 AM

Regeneron and Telix Announce Strategic Radiopharma Collaboration - The Manila Times

06:33 AM

06:30 AM

Regeneron taps Telix in $40M push for next-generation cancer drugs - Stock Titan

06:30 AM

05:52 AM

Sumitomo Mitsui Trust Group Inc. Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

05:52 AM

05:44 AM

Burney Co. Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN - National Today

05:44 AM

05:41 AM

Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU) - National Today

05:41 AM

02:03 AM

Sanofi (SNY) and Regeneron (REGN) Gain EU Approval for Dupixent in Young Children - GuruFocus

02:03 AM

01:28 AM

Sanofi, Regeneron’s Dupixent approved in EU for young children with chronic urticaria (SNY:NASDAQ) - Seeking Alpha

01:28 AM

01:15 AM

Dupixent Approved in EU for Treating Children with CSU - Intellectia AI

01:15 AM

01:10 AM

Regeneron and Sanofi Announce European Commission Approval of Dupixent for Chronic Spontaneous Urticaria in Children Aged 2 to 11 Years - Quiver Quantitative

01:10 AM

01:08 AM

Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria - The Manila Times

01:08 AM

12:59 PM

Australia's Telix Pharma announces strategic radiopharma collaboration worth $535 M with Regeneron - BioSpectrum Asia

12:59 PM

Apr 12, 2026